Latest news with #CorticalDisarrayMeasurement
Yahoo
27-05-2025
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
